2022 Psychopharmacology in Cancer Care: An Update for Clinicians of All Disciplines - On Demand

Thursday, May 19, 2022, 8:15 AM - Sunday, March 19, 2023, 11:00 PM

Clinicians have numerous tools at their disposal to help adult cancer patients dealing with symptoms of depression, anxiety, and other cancer sequelae. Psychiatric medications are most frequently prescribed to cancer patients by oncologists and general practitioners, however, psychiatric syndromes are often underdiagnosed and undertreated. Few oncology practices have dedicated psychiatric consultants familiar with the nuances of Psycho-Oncology. Even when patients receive psychotropic medications appropriately, they may have problems that arise before their next oncology visit or before they see the person who prescribed their psychiatric medications. Psychologists, nurses, and social workers play an essential role in identifying psychological and physical symptoms as well as both beneficial and problematic medication effects as they provide frontline psychosocial interventions and support for cancer patients.

This course is designed for the non-prescribing psycho-oncology clinician as well as the psychiatrist who is new to the world of Psycho-pharmaco-oncology. Oncologists, palliative care clinicians, advanced practice nurses, and oncology nurses will find this course useful as well. The course will focus on key target disorders and symptoms amenable to psychopharmacological intervention, including anxiety, depression, delirium, sleep disturbance, pain, fatigue, and weight and appetite loss. The course also include updates on COVID-19 related delirium and the use of novel interventions including ketamine, medical marijuana, and psilocybin for depression, anxiety, and pain. Participants will learn to identify psychological reactions to medical conditions or treatments; psychiatric presentations of medical conditions or treatments; medical presentations of psychiatric conditions and common medical complications of psychiatric conditions or treatments.

Basic information will be presented about medications used to alleviate Quality of Life symptoms that arise in the cancer setting from diagnosis to survivorship or end of life care, and the interface of psychotherapy and medication management. We will review why certain medications are used and why some are avoided, looking at potential benefits, unwanted side effects, and drug-drug interactions, since you may be the first person to identify a serious adverse event. The course will also enhance your ability to provide psychoeducation to patients regarding psychiatric medications.

This course is co-sponsored by the MSK Psycho-Oncology Education & Training Institute (POETI).

Target Audience

This course is intended for external (non-MSK) Psychiatrists, Psycho-oncologists, Oncologists, Palliative Care Physicians, Physician Assistants, Nurse Practitioners, Nurses, Psychologists, Social Workers and Counselors.

*Please note, if you are an MSK employee and would like to be notified of upcoming courses, including the 2023 Psychopharmacology in Cancer Care live course, please subscribe to receive MSK CME announcements.

On Demand Content

This on demand course contains over 9 recorded lectures and PDFs of PowerPoint presentations. Select the 'Register' tab at the top of this page to purchase this program. Once you have successfully registered, access to the course materials will be available under the 'Course Content' tab.

This on demand program will be available for purchase until December 19, 2022.
Access to the videos and claiming credit will be available until March 19, 2023.

1. Participants will learn basic psycho-pharmaco-oncology and how to hone essential clinical and observation skills to improve the quality of life, mental health and safety of their patients by understanding the basics of the psychophysiology of cancer.

On Demand Access Fees

• Physicians (MD, DO, MBBS, or equivalent): $75
• Residents, Fellows, Advanced Practice Providers, Nurses, Psychologists, Social Workers, Counselors, and All Other Healthcare Providers: $50

Registration Discounts/Promotions

• A registration discount is available for MSK Alumni and MSK Cancer Alliance members to attend a MSK CME course. If you are a member of one of these groups, contact [email protected] for details.

Please note that after your payment has been processed, no further promotional discount adjustments will be made to your registration.

Registration fees for this online CME activity are non-refundable.

Memorial Sloan Kettering Cancer Center is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

AMA Credit Designation Statement

Memorial Sloan Kettering Cancer Center designates this enduring material for a maximum of 6.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

 

Recorded/Review Date: April 23, 2022; Original Release Date: May 19, 2022; Termination Date: December 19, 2022

MSK Course Faculty 

Yesne Alici, MD
Clinical Director, Associate Attending Psychiatrist, Psychiatry Service
Medical Director, Biobehavioral Brain Health Clinic
Department of Psychiatry and Behavioral Sciences

William Breitbart, MD
Attending Psychiatrist, Chair
Department of Psychiatry and Behavioral Sciences
Attending Psychiatrist, Supportive Care Service
Department of Medicine

Alan Carver, MD
Attending Neurologist
Department of Neurology
Department of Medicine

Christian Bjerre Real, MD, MMCI
Research Fellow
Department of Psychiatry and Behavioral Sciences

Andrew Roth, MD
Attending Psychiatrist, Psychiatry Service
Department of Psychiatry and Behavioral Sciences

 

Relevant Financial Relationships

Mitigation of Relevant Financial Relationships

Memorial Sloan Kettering Cancer Center adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers, or others are required to disclose all financial relationships with ineligible companies (commercial interests). All relevant financial relationships have been mitigated prior to the commencement of the activity.